Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients

Abstract

Paroxetine is a phenylpiperidine compound which is a selective serotonin reuptake inhibitor (SSRI). Ninety-one hospitalised patients with a major depression (DSM-III) aged 65 and over from six Austrian and one German center were entered into the study, which compared the efficacy and tolerability of paroxetine versus amitriptyline. After 6 weeks both groups showed similarly good therapeutic results. In the paroxetine group, 64.3% of the patients had a 50% or more reduction of the HAMD total score compared to 58.1% in the amitriptyline group. Side effects were distributed similarly in both groups. Patients in the paroxetine group showed a higher incidence of anxiety and agitation; anticholinergic side effects were registered more often in the amitriptyline group.

This is a preview of subscription content, log in to check access.

References

  1. American Psychiatric Association (1980) DSM-III: diagnostic and statistical manual of mental disorders, 3rd edn. APA, Washington DC

  2. Buus Lassen F (1978) Potent and long lasting potentiation of two 5-hydroxy induced effects in mice by three selective 5-HT uptake inhibitors. Eur J Pharmacol 47:351–358

  3. Cohn JB, Crowder JE, Wilcox CS, Ryan PJ (1990) A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull 26:185–189

  4. De Vane CL (1992) Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 53[2, suppl]:13–20

  5. Dunbar GC, Cohn JB, Fabre LF, Feighner JP, Fieve RR, Mendels J, Shrivastava RK (1991) A comparison of paroxetine, imipramine and placebo in depressed out-patients. Br J Psychiatry 159:394–398

  6. Dunbar GC, Fuell DL (1992) The anti-anxiety and Anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 6[4, suppl]:81–90

  7. Feighner JP, Boyer WF (1992) Paroxetine in the treatment of depression: a comparison with imipramine and placebo. J Clin Psychiatry 53[2, suppl]:44–47

  8. Geretsegger C, Boehmer F, Ludwig M (1994) Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 9:25–29

  9. Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, Davies SO, Klein DF (1987) An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 7:329–332

  10. Guillibert E, Pelcier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y (1989) A double-blind, multicenter study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 80[350, suppl]:132–134

  11. Hamilton M (1960) A rating sclae for depression. J Neurol Neurosurg Psychiatry 23:56–62

  12. Hutchinson DR, Tong S, Moon CAL, Vince M, Clarke A (1992) Paroxetine in the treatment of elderly depressed patients in general practice: A double-blind comparison with amitriptyline. Int Clin Psychopharmacol 6[4, suppl]:43–52

  13. Jefferson JW (1975) A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med 37:160–179

  14. Laursen AL, Mikkelsen PL, Rasmussen S, Le Fevre Honore P (1985) Paroxetine in the treatment of depression — a randomized comparison with amitriptyline. Acta Psychiatr Scand 71:249–255

  15. Mertens C, Pintens H (1989) A double-blind, multicenter study of paroxetine and mianserin in depression. Acta Psychiatr Scand 80[350, suppl]:140

  16. Montgomery SA (1992) The advantages of paroxetine in different subgroups of depression. Int Clin Psychopharmacol 6[4, suppl]:91–100

  17. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389

  18. National Institute of Mental Health (1976) CGI. Clinical global Impressions. In: Guy (ed) ECDEU assessment manual for psychopharmacology. revised edn. Rockville, Maryland, pp 217–222

  19. Stuppaeck CH, Geretsegger C, Whitworth AB, Schubert H, Platz T, Koenig P, Hinterhuber H, Fleischhacker WW (1994) A multicenter double-blind trial of paroxetine vs. amitriptyline in depressed in-patients. J Clin Psychopharmacol 14:241–246

  20. Tignol J (1994) A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 13[2, suppl]:18–22

  21. Tulloch IF, Johnson AM (1992) The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 53[2, suppl]:7–12

Download references

Author information

Correspondence to C. Geretsegger.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Geretsegger, C., Fartacek, R., Stuppaeck, C.H. et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology 119, 277–281 (1995). https://doi.org/10.1007/BF02246291

Download citation

Key words

  • Paroxetine
  • Selective serotonin reuptake inhibitors
  • Depression
  • Elderly patients
  • Amitriptyline